scholarly journals Multiple sclerosis epidemiology in Latin America: An updated survey

2017 ◽  
Vol 3 (2) ◽  
pp. 205521731771505 ◽  
Author(s):  
Edgardo Cristiano ◽  
Juan Ignacio Rojas
Keyword(s):  
Multiple Sclerosis ◽  
Systematic Review ◽  
Latin America ◽  
North American ◽  
Epidemiological Data ◽  
Incidence Data ◽  
Epidemiological Features ◽  
Multiple Sclerosis Epidemiology

Novel epidemiological data have appeared in recent years in Latin America (LATAM). The objective of this study was to perform an updated systematic review of the epidemiology of the disease reported in LATAM. Methods We conducted a systematic review of published epidemiological articles from January 1995 to December 2016. Results Incidence data were found in four studies and ranged from 0.3 to 3 annual cases per 100,000 person-years. Prevalence was reported in 13 studies and ranged from 0.83 to 38.2 cases per 100,000 inhabitants. Two studies showed an increase in prevalence and incidence in the last five years in specific regions. Conclusion The study provides updated information on epidemiological features of MS in the region. The frequency reported is lower compared with some European and North American countries; however, due to recent observations, studies including follow-up assessment of prevalence and incidence should be conducted in the region.

The epidemiology of multiple sclerosis in Latin America and the Caribbean: a systematic review

2012 ◽  
Vol 19 (7) ◽  
pp. 844-854 ◽  
Author(s):  
E Cristiano ◽  
JI Rojas ◽  
M Romano ◽  
N Frider ◽  
G Machnicki ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Systematic Review ◽  
Latin America ◽  
Low Frequency ◽  
Epidemiological Data ◽  
Developed Countries ◽  
Epidemiological Studies ◽  
Incidence Data ◽  
Full Text Review ◽  
The Caribbean

The incidence and prevalence of multiple sclerosis (MS) varies geographically as shown through extensive epidemiological studies performed mainly in developed countries. Nonetheless, scant data is available in Latin America and the Caribbean (LAC). The objective of this review is to assess epidemiological data of MS in LAC. We conducted a systematic review of published articles and gray literature from January 1995 to May 2011. Twenty-two studies met the inclusion criteria after full-text review. Incidence data were found in only three studies and ranged from 0.3 to 1.9 annual cases per 100,000 person-years. Prevalence was reported in 10 studies and ranged from 0.83 to 21.5 cases per 100,000 inhabitants. The most prevalent subtype of MS was the relapsing–remitting form (48% to 91% of the series). No data about mortality were found. This study showed low frequency for MS in LAC compared with North American and European countries. The role of environmental and genetic factors should be well studied, providing new insights about its etiology.

Multiple sclerosis epidemiology in Asia and Oceania; A systematic review and meta-analysis

2021 ◽  
pp. 103119
Author(s):  
Ali Forouhari ◽  
Ghazale Taheri ◽  
Salari Mehri ◽  
Moosazadeh Mahmood ◽  
Masoud Etemadifar
Keyword(s):  
Multiple Sclerosis ◽  
Systematic Review ◽  
Meta Analysis ◽  
Multiple Sclerosis Epidemiology

Latitudinal prevalence gradient of multiple sclerosis in Latin America

2011 ◽  
Vol 17 (9) ◽  
pp. 1055-1059 ◽  
Author(s):  
J Risco ◽  
H Maldonado ◽  
L Luna ◽  
J Osada ◽  
P Ruiz ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Systematic Review ◽  
Latin America ◽  
Latin American ◽  
Prevalence Rates ◽  
Geographical Regions ◽  
Genetic And Environmental Factors ◽  
Latin American Countries ◽  
Crude Prevalence ◽  
Scarce Data

Background: Multiple sclerosis (MS) has a unique geographical distribution that reflects both genetic and environmental factors. Many studies have shown a positive correlation between MS frequency and latitude across both large and small geographical regions. However, scarce data have been published on the epidemiology of MS in Latin America and no study has evaluated latitudinal variation. Objective: To evaluate the effect of latitude on MS prevalence in Latin America. Methods: We conducted a systematic review of MS prevalence during January 2011. Prevalence rates were collected from eligible publications. The effect of latitude on prevalence was analyzed using linear regression. Results: A total of ten studies were eligible for analysis, corresponding to six countries, spanning from Panama to Argentina. The crude prevalence of MS ranged from 0.75 to 21.5 per 100,000. We found a strong and significant association between prevalence and latitude ( r2 0.8; p < 0.001) and determined an increase in prevalence of 0.33 per 100,000 per degree latitude. Conclusion: Our findings suggest a latitudinal prevalence gradient of MS in Latin American countries between Panama and Argentina.

scholarly journals Systematic Review of the Economics of Multiple Sclerosis in Latin America

2014 ◽  
Vol 17 (7) ◽  
pp. A394
Author(s):  
T.R. Einarson ◽  
B. Bereza ◽  
M. Machado
Keyword(s):  
Multiple Sclerosis ◽  
Systematic Review ◽  
Latin America

scholarly journals Optimizing outcomes in multiple sclerosis: consensus guidelines for the diagnosis and treatment of multiple sclerosis in Latin America

2011 ◽  
Vol 4 (6) ◽  
pp. 349-360 ◽  
Author(s):  
Adriana Carrá ◽  
Miguel Ángel Macías-Islas ◽  
Alberto Alan Gabbai ◽  
Jorge Correale ◽  
Carlos Bolaña ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Latin America ◽  
Latin American ◽  
Online Survey ◽  
Cost Effective ◽  
Differential Diagnoses ◽  
Effective Control ◽  
Therapeutic Recommendations ◽  
Latin American Countries

Objective: The prevalence of multiple sclerosis (MS) in Latin America varies across different studies but an intermediate risk and increased frequency of the disease have been reported in recent years. The circumstances of Latin American countries are different from those of Europe and North America, both in terms of differential diagnoses and disease management. Methods: An online survey on MS was sent to 855 neurologists in nine Latin American countries. A panel of nine experts in MS analyzed the results. Results: Diagnostic and therapeutic recommendations were outlined with special emphasis on the specific needs and circumstances of Latin America. The experts proposed guidelines for MS diagnosis, treatment, and follow up, highlighting the importance of considering endemic infectious diseases in the differential diagnoses of MS, the identification of patients at high risk of developing MS in order to maximize therapeutic opportunities, early treatment initiation, and cost-effective control of treatment efficacy, as well as global assessment of disability. Conclusions: The experts recommended that healthcare systems allocate a longer consultation time for patients with MS, which must be conducted by neurologists trained in the management of the disease. All drugs currently approved must be available in all Latin American countries and must be covered by healthcare plans. The expert panel supported the creation of a permanent forum to discuss future clinical and therapeutic recommendations that may be useful in Latin American countries.

scholarly journals Latin American algorithm for treatment of relapsing-remitting multiple sclerosis using disease-modifying agents

2012 ◽  
Vol 70 (10) ◽  
pp. 799-806 ◽  
Author(s):  
Alessandro Finkelsztejn ◽  
Alberto Alain Gabbai ◽  
Yara Dadalti Fragoso ◽  
Adriana Carrá ◽  
Miguel Angel Macías-Islas ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Latin America ◽  
Latin American ◽  
North American ◽  
Scientific Evidence ◽  
Relapsing Remitting ◽  
Disease Modifying ◽  
Remitting Multiple Sclerosis ◽  
Disease Modifying Agents ◽  
Relapsing Remitting Multiple Sclerosis

OBJECTIVE: It is estimated that circa 50,000 individuals have relapsing-remitting multiple sclerosis in Latin America. European and North-American algorithms for the treatment of multiple sclerosis do not foresee our regional difficulties and the access of patients to treatment. METHODS: The Latin American Multiple Sclerosis Forum is an independent and supra-institutional group of experts that has assessed the latest scientific evidence regarding efficacy and safety of disease-modifying treatments. Accesses to treatment and pharmacovigilance programs for each of the eight countries represented at the Forum were also analyzed. RESULTS: A specific set of guidelines based upon evidence-based recommendations was designed for Latin America. Future perspectives of multiple sclerosis treatment were also discussed. CONCLUSIONS: The present paper translated an effort from representatives of eight countries discussing a matter that cannot be adapted to our region directly from purely European and North-American guidelines for treatment.

1588: The Bicalutamide Early Prostate Cancer Program: Findings of the North American Trial at 7.7 Years' Median Follow-Up

2006 ◽  
Vol 175 (4S) ◽  
pp. 511-512
Author(s):  
David G. McLeod ◽  
Ira Klimberg ◽  
Donald Gleason ◽  
Gerald Chodak ◽  
Thomas Morris ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
North American ◽  
Early Prostate Cancer ◽  
The North ◽  
Cancer Program

Therapy of post-stroke depression – a systematic review

2013 ◽  
Vol 10 (02) ◽  
pp. 108-129 ◽  
Author(s):  
W. Gaebel ◽  
W. Wannagat ◽  
J. Zielasek
Keyword(s):  
Systematic Review ◽  
Large Scale ◽  
Repetitive Transcranial Magnetic Stimulation ◽  
Placebo Control ◽  
Post Stroke ◽  
Pharmacological Studies ◽  
Post Stroke Depression ◽  
Control Procedures ◽  
Antidepressant Pharmacotherapy

SummaryWe performed a systematic review of randomized placebo-controlled pharmacological and non-pharmacological trials for the therapy and prevention of post-stroke depression that have been published between 1980 and 2011. We initially identified 2 260 records of which 28 studies were finally included into this review. A meta-analytic approach was hampered by considerable differences regarding the kinds of therapeutic regimens and the study durations. Modest effects favoring treatment of post-stroke depression could be found for pharmacological treatment as well as repetitive transcranial magnetic stimulation. For the prevention of post-stroke depression, antidepressant pharmacotherapy showed promising results. However, large-scale studies with better standardized study populations, optimized placebo control procedures in non-pharmacological studies, and replication in larger follow-up studies are still necessary to find the optimal therapeutic regimens to prevent and treat post-stroke depression.

Sign in / Sign up

Export Citation Format

Share Document